PDCD1 and neoplasm: These findings were extended in an immunocompetent model of orthotopic murine ATC by showing that the combination of the BRAF inhibitor (i.e., PLX4720) and anti-PD-1/PD-L1 mAbs reduced tumor volume and improved survival [241].